ATE398129T1 - Reverse-turn-mimetika und diese betreffendes verfahren - Google Patents
Reverse-turn-mimetika und diese betreffendes verfahrenInfo
- Publication number
- ATE398129T1 ATE398129T1 AT02781937T AT02781937T ATE398129T1 AT E398129 T1 ATE398129 T1 AT E398129T1 AT 02781937 T AT02781937 T AT 02781937T AT 02781937 T AT02781937 T AT 02781937T AT E398129 T1 ATE398129 T1 AT E398129T1
- Authority
- AT
- Austria
- Prior art keywords
- reverse
- disease
- turn
- biologically active
- disclosed
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 230000004156 Wnt signaling pathway Effects 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 238000002399 angioplasty Methods 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000000032 diagnostic agent Substances 0.000 abstract 1
- 229940039227 diagnostic agent Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003278 mimic effect Effects 0.000 abstract 1
- 208000030761 polycystic kidney disease Diseases 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/14—Solid phase synthesis, i.e. wherein one or more library building blocks are bound to a solid support during library creation; Particular methods of cleavage from the solid support
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Structural Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pinball Game Machines (AREA)
- Details Of Garments (AREA)
- Ceramic Products (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97647001A | 2001-10-12 | 2001-10-12 | |
| US8744302A | 2002-03-01 | 2002-03-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE398129T1 true ATE398129T1 (de) | 2008-07-15 |
Family
ID=26776979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02781937T ATE398129T1 (de) | 2001-10-12 | 2002-10-11 | Reverse-turn-mimetika und diese betreffendes verfahren |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1444235B1 (de) |
| JP (1) | JP4387793B2 (de) |
| KR (1) | KR100910307B1 (de) |
| CN (1) | CN100475816C (de) |
| AT (1) | ATE398129T1 (de) |
| AU (1) | AU2002348649B9 (de) |
| CA (1) | CA2462922C (de) |
| DE (1) | DE60227093D1 (de) |
| ES (1) | ES2310215T3 (de) |
| WO (1) | WO2003031448A1 (de) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040072831A1 (en) * | 2001-10-12 | 2004-04-15 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| US7671054B1 (en) | 2001-10-12 | 2010-03-02 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| US7232822B2 (en) | 2001-10-12 | 2007-06-19 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| US7566711B2 (en) | 2001-10-12 | 2009-07-28 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| US7576084B2 (en) * | 2001-10-12 | 2009-08-18 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| US8080657B2 (en) | 2001-10-12 | 2011-12-20 | Choongwae Pharma Corporation | Compounds of reverse turn mimetics and the use thereof |
| WO2005021025A2 (en) * | 2003-08-28 | 2005-03-10 | Choongwae Pharma Corporation | MODULATION OF β-CATENIN/TCF ACTIVATED TRANSCRIPTION |
| US20070129353A1 (en) | 2005-11-08 | 2007-06-07 | Michael Kahn | Alpha-helix mimetics and method relating to the treatment of cancer stem cells |
| KR100712667B1 (ko) * | 2006-04-11 | 2007-05-02 | 재단법인서울대학교산학협력재단 | 신규한 디아자 헤테로고리 유도체 및 그의 고체상 제조방법 |
| JP2009538903A (ja) * | 2006-05-30 | 2009-11-12 | チュンウェ ファーマ コーポレーション | 幹細胞分化の誘導または抑制のための組成物 |
| DE102007011912A1 (de) * | 2007-03-13 | 2008-09-18 | Sanofi-Aventis | Verfahren für das Erzeugen von Peptidbibliotheken und deren Verwendung |
| RU2512538C2 (ru) * | 2008-06-06 | 2014-04-10 | Присм Байолэб Корпорейшн | Альфа-спиральные миметики и способы, связанные с ними |
| US8691819B2 (en) | 2008-10-14 | 2014-04-08 | Prism Biolab Corporation | Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions |
| AU2010237633B2 (en) * | 2009-04-15 | 2015-09-17 | Jw Pharmaceutical Corporation | Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof |
| EP2427451B1 (de) | 2009-05-07 | 2019-03-20 | PRISM BioLab Co., Ltd. | Alpha-helix-mimetika und damit in zusammenhang stehende methoden |
| JPWO2011096440A1 (ja) | 2010-02-03 | 2013-06-10 | 株式会社 ＰＲＩＳＭ ＢｉｏＬａｂ | 天然変性タンパク質に結合する化合物およびそのスクリーニング方法 |
| KR101892575B1 (ko) * | 2010-10-14 | 2018-08-31 | 제이더블유중외제약 주식회사 | 리버스-턴 유사체의 신규한 화합물 및 그 제조방법과 용도 |
| JP2014509298A (ja) * | 2011-02-25 | 2014-04-17 | 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ | アルファへリックスミメティック及びその関連の方法 |
| CN103930113B (zh) * | 2011-08-09 | 2016-08-17 | Jw制药公司 | 用于预防和治疗非小细胞肺癌的包含吡嗪并三嗪衍生物的组合物 |
| US9700569B2 (en) | 2012-12-12 | 2017-07-11 | Prism Pharma Co., Ltd. | Prevention or treatment agent for hepatic fibrosis |
| US9174998B2 (en) * | 2013-12-25 | 2015-11-03 | Eisai R&D Management Co., Ltd. | (6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound |
| CA2988707C (en) | 2015-06-16 | 2023-10-10 | Eisai R&D Management Co., Ltd. | Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer |
| KR102559211B1 (ko) | 2015-06-23 | 2023-07-25 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | (6S,9aS)-N-벤질-8-({6-[3-(4-에틸피페라진-1-일)아제티딘-1-일]피리딘-2-일}메틸)-6-(2-플루오로-4-하이드록시벤질)-4,7-디옥소-2-(프로프-2-엔-1-일)헥사하이드로-2H-피라지노[2,1-c][1,2,4]트리아진-1(6H)-카복사마이드의 결정 |
| EP3366687B1 (de) * | 2015-09-18 | 2020-04-29 | National University Corporation Tottori University | Suppresions- und regnerationsförderner effekt einer verbindung mit niedrigem molekulargewicht auf krebs und fibrose |
| CN110072528B (zh) | 2017-02-08 | 2022-04-26 | 卫材R&D管理有限公司 | 治疗肿瘤的药物组合物 |
| WO2018212202A1 (en) | 2017-05-16 | 2018-11-22 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
| WO2021086909A1 (en) | 2019-10-29 | 2021-05-06 | Eisai R&D Managment Co., Ltd. | Combination of a pd-1 antagonist, a vegfr/fgfr/ret tyrosine kinase inhibitor and a cbp/beta-catenin inhibitor for treating cancer |
| JP7748118B2 (ja) * | 2021-01-20 | 2025-10-02 | 株式会社 PRISM BioLab | 新規二環性化合物 |
| CN116925081A (zh) * | 2022-04-11 | 2023-10-24 | 中国科学院上海药物研究所 | 一种环肽类化合物及其应用 |
| CN117105821A (zh) * | 2023-04-18 | 2023-11-24 | 重庆普佑制药有限公司 | 一种沙库比曲中间体的制备方法 |
| WO2025174646A1 (en) * | 2024-02-12 | 2025-08-21 | Albert Einstein College Of Medicine | Inhibitors of beta-catenin c-terminal domain and methods of use |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5929237A (en) * | 1995-10-27 | 1999-07-27 | Molecumetics Ltd. | Reverse-turn mimetics and methods relating thereto |
| US6013458A (en) * | 1995-10-27 | 2000-01-11 | Molecumetics, Ltd. | Reverse-turn mimetics and methods relating thereto |
| US6184223B1 (en) * | 1995-10-27 | 2001-02-06 | Molecumetics Ltd. | Reverse-turn mimetics and methods relating thereto |
-
2002
- 2002-10-11 AT AT02781937T patent/ATE398129T1/de not_active IP Right Cessation
- 2002-10-11 DE DE60227093T patent/DE60227093D1/de not_active Expired - Lifetime
- 2002-10-11 EP EP02781937A patent/EP1444235B1/de not_active Expired - Lifetime
- 2002-10-11 KR KR1020047005346A patent/KR100910307B1/ko not_active Expired - Fee Related
- 2002-10-11 JP JP2003534431A patent/JP4387793B2/ja not_active Expired - Fee Related
- 2002-10-11 AU AU2002348649A patent/AU2002348649B9/en not_active Ceased
- 2002-10-11 WO PCT/KR2002/001901 patent/WO2003031448A1/en not_active Ceased
- 2002-10-11 CA CA2462922A patent/CA2462922C/en not_active Expired - Lifetime
- 2002-10-11 ES ES02781937T patent/ES2310215T3/es not_active Expired - Lifetime
- 2002-10-11 CN CNB028225678A patent/CN100475816C/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002348649B9 (en) | 2008-06-19 |
| CA2462922C (en) | 2010-05-25 |
| CA2462922A1 (en) | 2003-04-17 |
| EP1444235B1 (de) | 2008-06-11 |
| KR100910307B1 (ko) | 2009-08-03 |
| WO2003031448A1 (en) | 2003-04-17 |
| AU2002348649B2 (en) | 2008-05-08 |
| CN100475816C (zh) | 2009-04-08 |
| EP1444235A1 (de) | 2004-08-11 |
| CN1585770A (zh) | 2005-02-23 |
| ES2310215T3 (es) | 2009-01-01 |
| JP2005505596A (ja) | 2005-02-24 |
| KR20040045504A (ko) | 2004-06-01 |
| JP4387793B2 (ja) | 2009-12-24 |
| DE60227093D1 (de) | 2008-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60227093D1 (de) | Reverse-turn-mimetika und diese betreffendes verfahren | |
| WO2004093828A3 (en) | Reverse-turn mimetics and method relating thereto | |
| WO2005116032A3 (en) | Reverse-turn mimetics and method relating thereto | |
| ATE203025T1 (de) | Reverse-turnmimetika und damit zusammenhängendes verfahren | |
| ATE301656T1 (de) | Reverse-turnmimetika und damit zusammenhängendes verfahren | |
| WO2009051399A3 (en) | Novel compounds of reverse turn mimetics and the use thereof (1) | |
| NO308601B1 (no) | Tricykliske benzazepiner og farmasøytisk preparat inneholdende disse | |
| ATE474854T1 (de) | Rsv neutralisierende antikörper mit sehr hohen affinität | |
| ATE403657T1 (de) | Chemische verbindungen | |
| EA200001188A1 (ru) | ПИРРОЛО[2,3-d]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ | |
| WO2002050066A3 (en) | Pyrazole compounds useful as protein kinase inhibitors | |
| DK0784683T3 (da) | TIE-2-ligander, fremgangsmåder til dannelse af disse og anvendelser deraf | |
| BR0214485A (pt) | 3-cianoquinolinas como inibidores de egf-r e her2 quinases | |
| WO2006094187A3 (en) | Phthalazine, aza- and diaza-phthalazine compounds and methods of use | |
| ATE517920T1 (de) | Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1) | |
| BR0109598A (pt) | Inibidores de quinase de proteìna tricìclicos | |
| WO2002081745A3 (en) | Genes involved in osteogenesis, and methods of use | |
| ATE235551T1 (de) | Ligand (tie ligand-4) vom tie-2 rezeptor und dessen verwendungen | |
| WO2001042243A3 (en) | Protein kinase inhibitors | |
| WO2002092010A3 (en) | Reverse-turn mimetics and methods relating thereto | |
| ATE393170T1 (de) | Humanisierter antikörper gegen fibroblastenwachstumsfaktor 8 und fragment des antikörpers | |
| BR0318325A (pt) | miméticos de beta-fita e método relacionado aos mesmos | |
| EP1436279A4 (de) | Chemische verbindungen | |
| EP1078003A4 (de) | Plasmin-inhibitoren aus der australischen braunen schlange (pseudonaja textilis textilis) | |
| WO2001035951A3 (en) | Aryl nitrone therapeutics and methods for treating inflammatory bowel disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |